However, the traditional ‘brute force’ drug discovery process has limited the true potential of this space. Multiple breakthroughs, from penicillin to statins to various oncology drugs, have resulted from microbial natural product drug discovery. We can learn from nature how to fight disease. “Metabolites from microbes such as fungi and bacteria have evolved over millions of years to potently inhibit certain proteins, many of which are implicated in human diseases. “We are thrilled to have the continued support and confidence of our top-tier investor syndicate as we advance our novel platform for targeted small molecule drug discovery,” said Maureen Hillenmeyer, Ph.D., co-founder and CEO of Hexagon. Existing investors, including The Column Group, Two Sigma Ventures, 8VC, and Nextech, participated in the Series B round, joined by additional new investors, including Canada Pension Plan Investment Board (CPP Investments). MENLO PARK, Calif., February 13, 2023- Hexagon Bio, a biopharmaceutical company pioneering the discovery of medicines encoded in the global metagenome, today announced that it has raised a $77.3 million Series B financing and made key appointments to its leadership team. Victor Cee, Ph.D., former research project team leader for LUMAKRAS® (sotorasib) at Amgen, joins Hexagon as SVP, Drug Discovery. Tara Arvedson, Ph.D., former Executive Director of Oncology Research at Amgen, who joined Hexagon last year as SVP, Research, has been promoted to Chief Scientific Officer.Hexagon’s interdisciplinary platform enables broad opportunities across multiple therapeutic areas company initially focused on oncology and infectious diseases. Hexagon Bio Raises $77.3 Million Series B Financing and Strengthens Leadership to Expand Novel Computational Discovery Platform and Advance Microbial Genome-Derived Small Molecules VCPro Database is available in both Windows and macOS versions. The most reliable, up-to-date and affordable venture capital directory of its kind. VCPro Database 2023 26th Edition - a downloadable and searchable venture capital database with 6,900+ venture capital and private equity firms worldwide. Hexagon Bio Raises $77.3 Million Series B Financing and Strengthens Leadership to Expand Novel Computational Discovery Platform.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |